Schering-Plough says it expects second-quarter profits to be on a parwith last year's figure of $0.43 cents per share, but declined to make any full-year estimates, as the firm continues to be haunted by manufacturing deficiencies found by the US Food and Drug Administration at its facilities in New Jersey, USA, as well as in Las Piedras and Manati, Puerto Rico (Marketletter July 2).
Richard Kogan, the company's chief executive, hosted a meeting with analysts and portfolio managers in New York, where he said: "for now and the rest of 2001, we will be taking a quarter-by-quarter approach, providing periodic updates as the year progresses." The problems with the FDA are clearly causing a lot of uncertainty for S-P and Mr Kogan added that "we are working through our priorities [and] believe we are making progress, but there is still much to do."
Stock buyback suspended
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze